Category: Q3Syndicate content

Price pressure weighs on Philips as lighting split looms

October 20, 2014 by MassDevice

Downward pricing pressure pushes Philips into a slaes-and-revenue decline, as its healthcare business sees a nearly 20% EBITA slide.

Price pressure weighs on Philips as lighting split looms

Valeant says may raise Allergan bid; beats on profit

October 20, 2014 by MassDevice

Valeant Pharmaceuticals says it might up the ante in its hostile takeover bid for Allergan as it reports higher-than-forecast profits for its 3rd quarter.

Valeant says may raise Allergan bid; beats on profit

GE CEO Immelt: Global experience got Flannery the top spot at GE Healthcare

October 20, 2014 by Brad Perriello

John Flannery's experience in global markets landed him the top spot at GE Healthcare, where he replaced John Dineen, GE CEO Jeffrey Immelt told analysts last week.

GE CEO Immelt: Global experience got Flannery the top spot at GE Healthcare

Stryker edges The Street despite plunging Q3 profits

October 16, 2014 by Brad Perriello

Stryker edges expectations on Wall Street despite a nearly 45% profit slide as it posts strong revenue growth and expands its footprint in Europe.

Stryker edges The Street despite plunging Q3 profits

Getinge trims sales forecast as Q3 falls short

October 16, 2014 by MassDevice

Getinge lowers its sales forecast for the rest of the year amid uncertain earnings outlook, sending share prices plunging in Stockholm.

Getinge trims sales forecast as Q3 falls short

St. Jude Medical CEO: CardioMEMS the 'single most important new growth driver'

October 16, 2014 by Brian Johnson

St. Jude Medical CEO Dan Starks is bullish on the potential for recent acquisition CardioMEMS to tap the $1 billion market for treating heart failure.

St. Jude Medical CEO: CardioMEMS the 'single most important new growth driver' in portfolio

Medical products push Baxter profit above estimate

October 16, 2014 by MassDevice

Baxter's 3rd-quarter profits beat expectations, driven by its medical product business, but shares slide on a lowered earnings forecast.

Medical products push Baxter profit above estimate

(Reuters) - Medical device and drug maker Baxter (NYSE:BAX) reported a higher-than-expected quarterly profit, as sales in its medical products business continued to grow.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp